GR 131663Alternative Names: AH 017
Latest Information Update: 06 Dec 2000
At a glance
- Originator GlaxoSmithKline
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Melatonin MT1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Sleep disorders
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 12 Mar 1997 No-Development-Reported for Sleep disorders in United Kingdom (Unknown route)